梅里埃診斷產(chǎn)品（上海）有限公司
所屬行業(yè)：醫(yī)療設(shè)備/器械 企業(yè)規(guī)模：101-500人 企業(yè)性質(zhì)：外企獨資
梅里埃診斷產(chǎn)品（上海）有限公司招聘職位列表職位名稱 工作地點 職位類型 發(fā)布日期 所屬機構(gòu) 注冊部實習(xí)生（beijing or shanghai） 北京 上海 兼職/實習(xí) 2月07日 上海總部 HR Intern 上海 兼職/實習(xí) 2月07日 上?？偛?marketing intern 上海 兼職/實習(xí) 1月13日 上?？偛?梅里埃診斷產(chǎn)品（上海）有限公司簡介
Introduction of bioMerieux 生物梅里埃公司創(chuàng)建於1963年，公司依賴自身的科技研究和工業(yè)生產(chǎn)資源，始終致力於開發(fā)作為醫(yī)療和工業(yè)用途的體外診斷產(chǎn)品。 集團專門設(shè)計、開發(fā)、生產(chǎn)和推廣應(yīng)用在臨床和工業(yè)的系統(tǒng)。生物梅里埃的診斷系統(tǒng)是由試劑、 儀器和軟件組成，主要是為傳染病、工業(yè)微生物控制、心血管病和腫瘤病等四個主要策略性領(lǐng)域來設(shè)計。 在2007年，公司銷售額為10億6千3百萬歐元，集團共有11個生產(chǎn)基地和9個研究中心，分布于歐洲、北美洲和南美洲。集團全球擁有38個辦事處，至2007年12月31日集團員工超過5,700人。 生物梅里埃公司產(chǎn)品有兩個應(yīng)用領(lǐng)域 : 臨床和工業(yè)，臨床市場占總銷售額的85.5%，而工業(yè)市場占14.5%。工業(yè)的應(yīng)用主要在食品、藥品和化妝品的微生物分析，增長非常迅速，生物梅里埃是全球體外診斷領(lǐng)域的第八大生產(chǎn)商。 生物梅里埃中國有限公司已經(jīng)20年的發(fā)展，自動化微生物鑒定分析系統(tǒng)的用戶已達1400余家，自動微生物培養(yǎng)系統(tǒng)已達700余家，全自動細菌計數(shù)系統(tǒng)60余臺，手工產(chǎn)品用戶覆蓋全國的省市70%以上。同時公司擁有數(shù)十名微生物臨床及工業(yè)領(lǐng)域?qū)I(yè)人員和工程技術(shù)人員，其中許多人員都來自檢驗一線，擁有豐富的檢驗經(jīng)驗和儀器維修經(jīng)驗。全面負責(zé)生物梅里埃公司產(chǎn)品的銷售，儀器的安裝、維護及保養(yǎng)，以及用戶的培訓(xùn)及技術(shù)支持。 生物梅里埃公司擁有完善的產(chǎn)品策略、銷售策略和市場發(fā)展策略以全面的技術(shù)支持作後盾，為用戶提供感染病檢測產(chǎn)品及“全面解決問題”的服務(wù)是生物梅里埃公司的宗旨。相信會為您提供不斷完善的產(chǎn)品和令您滿意的服務(wù)。 bioMérieux by Alain Mérieux bioMérieux’s mission is to contribute to the improvement of public health worldwide through in vitro diagnostics. Throughout its history, our company has committed to four priorities, which today, represent its strength: • Our independence and expertise in the field of in vitro diagnostics allow us to respond rapidly in today’s complex environment and to form partnerships that are vital to our scientific and international growth. • Our international scope, with 84% of sales coming from outside of France. Established in 150 countries, with 39 subsidiaries and an extensive network of distributors, we are close to our customers, wherever they may be, and provide a line of products tailored to the realities of each region. • 45 years of experience and know-how in the field of infectious diseases allows bioMérieux, a world leader in microbiology, to respond to major public health issues, and affirm its position as a key player in clinical diagnostics and industrial microbiological quality control. • Scientific and technological innovation is at the heart of the bioMérieux strategy. It has enabled us to extend our expertise to the fields of cancer and cardiovascular diseases, complementing that of infectious diseases. bioMérieux dedicates considerable resources to R&D (over 12% of its sales), pursuing an ambitious policy based on multidisciplinary internal teams and a network of international partnerships and scientific affiliations. bioMérieux is part of the Mérieux Alliance group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.
bioMérieux is committed to serving a medicine that is continually more reactive, preventive and personalized in order to improve the quality of patient care. This is why our teams are located all over the world. They are at work developing diagnostic systems and reagents that respond perfectly to the demands of physicians and biologists, while anticipating scientific and technological developments. We also rely on the support of our shareholders, partners in our development, who through their continued confidence, allow us to envision the diagnostics of tomorrow.
Our Strategy A strategy putting patients first Our strategy is focused on pathologies and meeting the needs of clinicians, patients and consumers. We concentrate on infectious diseases - in particular, sepsis, hospital-acquired infections, tuberculosis, AIDS, and hepatitis - as well as on tests delivering high medical value for cancers (breast, colon, prostate) and emergency cardiovascular diseases. In applications for the agri-food, pharmaceutical and cosmetic industries, bioMérieux aspires to be the undisputed leader.
Corporate Social Responsibility As a corporate citizen, bioMérieux has made a long-term commitment to the following actions: • Improving access to diagnostics through our Public Health Department, focused on HIV/AIDS and tuberculosis. • Supporting public health initiatives in limited-resource countries through the Mérieux foundations and our constant commitment to the programs of major international organizations. • Upholding the Global Compact’s Principles: Since 2003, bioMérieux has been a member of the Global Compact, an international initiative under the auspices of the United Nations that aims to address the problems generated by globalization. • Being active in the local communities of our sites and subsidiaries, supporting charitable and cultural initiatives.
電子郵箱： hr-china@biomerieux.com 企業(yè)網(wǎng)址： http://www.biomerieux.com
梅里埃診斷產(chǎn)品（上海）有限公司招聘職位列表職位名稱 工作地點 職位類型 發(fā)布日期 所屬機構(gòu) 注冊部實習(xí)生（beijing or shanghai） 北京 上海 兼職/實習(xí) 2月07日 上海總部 HR Intern 上海 兼職/實習(xí) 2月07日 上?？偛?marketing intern 上海 兼職/實習(xí) 1月13日 上?？偛?梅里埃診斷產(chǎn)品（上海）有限公司簡介
Introduction of bioMerieux 生物梅里埃公司創(chuàng)建於1963年，公司依賴自身的科技研究和工業(yè)生產(chǎn)資源，始終致力於開發(fā)作為醫(yī)療和工業(yè)用途的體外診斷產(chǎn)品。 集團專門設(shè)計、開發(fā)、生產(chǎn)和推廣應(yīng)用在臨床和工業(yè)的系統(tǒng)。生物梅里埃的診斷系統(tǒng)是由試劑、 儀器和軟件組成，主要是為傳染病、工業(yè)微生物控制、心血管病和腫瘤病等四個主要策略性領(lǐng)域來設(shè)計。 在2007年，公司銷售額為10億6千3百萬歐元，集團共有11個生產(chǎn)基地和9個研究中心，分布于歐洲、北美洲和南美洲。集團全球擁有38個辦事處，至2007年12月31日集團員工超過5,700人。 生物梅里埃公司產(chǎn)品有兩個應(yīng)用領(lǐng)域 : 臨床和工業(yè)，臨床市場占總銷售額的85.5%，而工業(yè)市場占14.5%。工業(yè)的應(yīng)用主要在食品、藥品和化妝品的微生物分析，增長非常迅速，生物梅里埃是全球體外診斷領(lǐng)域的第八大生產(chǎn)商。 生物梅里埃中國有限公司已經(jīng)20年的發(fā)展，自動化微生物鑒定分析系統(tǒng)的用戶已達1400余家，自動微生物培養(yǎng)系統(tǒng)已達700余家，全自動細菌計數(shù)系統(tǒng)60余臺，手工產(chǎn)品用戶覆蓋全國的省市70%以上。同時公司擁有數(shù)十名微生物臨床及工業(yè)領(lǐng)域?qū)I(yè)人員和工程技術(shù)人員，其中許多人員都來自檢驗一線，擁有豐富的檢驗經(jīng)驗和儀器維修經(jīng)驗。全面負責(zé)生物梅里埃公司產(chǎn)品的銷售，儀器的安裝、維護及保養(yǎng)，以及用戶的培訓(xùn)及技術(shù)支持。 生物梅里埃公司擁有完善的產(chǎn)品策略、銷售策略和市場發(fā)展策略以全面的技術(shù)支持作後盾，為用戶提供感染病檢測產(chǎn)品及“全面解決問題”的服務(wù)是生物梅里埃公司的宗旨。相信會為您提供不斷完善的產(chǎn)品和令您滿意的服務(wù)。 bioMérieux by Alain Mérieux bioMérieux’s mission is to contribute to the improvement of public health worldwide through in vitro diagnostics. Throughout its history, our company has committed to four priorities, which today, represent its strength: • Our independence and expertise in the field of in vitro diagnostics allow us to respond rapidly in today’s complex environment and to form partnerships that are vital to our scientific and international growth. • Our international scope, with 84% of sales coming from outside of France. Established in 150 countries, with 39 subsidiaries and an extensive network of distributors, we are close to our customers, wherever they may be, and provide a line of products tailored to the realities of each region. • 45 years of experience and know-how in the field of infectious diseases allows bioMérieux, a world leader in microbiology, to respond to major public health issues, and affirm its position as a key player in clinical diagnostics and industrial microbiological quality control. • Scientific and technological innovation is at the heart of the bioMérieux strategy. It has enabled us to extend our expertise to the fields of cancer and cardiovascular diseases, complementing that of infectious diseases. bioMérieux dedicates considerable resources to R&D (over 12% of its sales), pursuing an ambitious policy based on multidisciplinary internal teams and a network of international partnerships and scientific affiliations. bioMérieux is part of the Mérieux Alliance group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.
bioMérieux is committed to serving a medicine that is continually more reactive, preventive and personalized in order to improve the quality of patient care. This is why our teams are located all over the world. They are at work developing diagnostic systems and reagents that respond perfectly to the demands of physicians and biologists, while anticipating scientific and technological developments. We also rely on the support of our shareholders, partners in our development, who through their continued confidence, allow us to envision the diagnostics of tomorrow.
Our Strategy A strategy putting patients first Our strategy is focused on pathologies and meeting the needs of clinicians, patients and consumers. We concentrate on infectious diseases - in particular, sepsis, hospital-acquired infections, tuberculosis, AIDS, and hepatitis - as well as on tests delivering high medical value for cancers (breast, colon, prostate) and emergency cardiovascular diseases. In applications for the agri-food, pharmaceutical and cosmetic industries, bioMérieux aspires to be the undisputed leader.
Corporate Social Responsibility As a corporate citizen, bioMérieux has made a long-term commitment to the following actions: • Improving access to diagnostics through our Public Health Department, focused on HIV/AIDS and tuberculosis. • Supporting public health initiatives in limited-resource countries through the Mérieux foundations and our constant commitment to the programs of major international organizations. • Upholding the Global Compact’s Principles: Since 2003, bioMérieux has been a member of the Global Compact, an international initiative under the auspices of the United Nations that aims to address the problems generated by globalization. • Being active in the local communities of our sites and subsidiaries, supporting charitable and cultural initiatives.
電子郵箱： hr-china@biomerieux.com 企業(yè)網(wǎng)址： http://www.biomerieux.com